Sector News

Alexion Names David Hallal COO

September 18, 2014
Life sciences
(RTTNews) – Alexion Pharmaceuticals, Inc., whose durg Soliris treats two rare diseases, Wednesday said it is promoting David Hallal to the newly created position of chief operating officer.
 
Hallal, who joined the company in 2006, was previously its executive vice president and chief commercial officer. He led the launch of Soliris. Before Alexion, he was worked at Biogen Idec and Amgen.
 
The company also promoted two members of the management to executive vice president from vice president: Chief Human Resources Officer Clair Carmichael ; and General Counsel John Moriarty.
 
The company further said it appointed Edward Miller to the nearly created position of Senior Vice President and Chief Compliance Officer.
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]